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Summary box
What is already known about this subject?
 ► Mutational load has been shown to help risk-strat-
ify those that may progress from non-dysplastic 
Barrett’s oesophagus to dysplastic disease.
 ► Management of patients with Barrett’s oesophagus 
and indefinite for dysplasia is challenging and risk 
stratification tools are lacking.
What are the new findings?
 ► This pilot study shows that mutational load may be 
able to risk-stratify which patients progress to high-
grade dysplasia.
How might it impact on clinical practice in the 
foreseeable future?
 ► If our results are reproducible in large studies, then 
mutational load may be an option to risk-stratify pa-
tients with Barrett’s oesophagus and indefinite for 
dysplasia.
ABSTRACT
Background and aims Mutational load (ML) has been 
shown to help risk-stratify those that may progress from 
non-dysplastic Barrett’s oesophagus (BE) to dysplastic 
disease. Management of patients with BE and indefinite 
for dysplasia (BE-IND) is challenging and risk stratification 
tools are lacking. The aim of this pilot study is to evaluate 
the utility of ML for risk stratification in patients with BE-
IND.
Methods This is a single-centre, retrospective pilot 
study evaluating ML quantification in patients with BE-
IND. Histology at follow-up endoscopy at least 1 year 
after the baseline endoscopy was used to determine if a 
patient progressed to low or high dysplasia. The ML levels 
were then compared among patients who progressed to 
dysplasia versus those who did not.
Results Thirty-five patients who met the inclusion criteria 
were identified, and seven met the exclusion criteria. 
Twenty-eight patients were analysed, of whom eight 
progressed to low-grade dysplasia (6) and high-grade 
dysplasia (2). Seven of these eight patients had some 
level of genomic instability detected in their IND biopsy 
(ML ≥0.5). Ten of the 20 (50%) who did not progress 
had no ML level. At an ML cut-off above 1.5, the risk of 
progression to high-grade dysplasia was 33% vs 0% 
(p=0.005), with a sensitivity of 100% and a specificity of 
85%.
Conclusion These results indicate that ML may be able to 
risk-stratify progression to high-grade dysplasia in BE-IND. 
Larger studies are needed to confirm these findings.
IntroductIon
Barrett’s oesophagus (BE) is defined as a 
change from normal oesophageal squamous 
epithelium to metaplastic columnar epithe-
lium with goblet cells, usually in association 
with gastro-oesophageal reflux disease.1 It is 
a major risk factor for oesophageal adeno-
carcinoma. Despite recommendations for 
screening and surveillance in Barrett’s, the 
incidence of oesophageal adenocarcinoma 
continues to rise.2 It is estimated that 5.6% of 
the adult population have BE in the USA.1 The 
only currently used biomarker for risk strati-
fication of BE is dysplasia. However finding 
and appropriately classifying dysplasia can be 
difficult. Often dysplasia is focal and finding 
it can be challenging given most sampling 
techniques sample a minority of the Barrett’s 
mucosa. Dysplasia in BE has been classified 
in a three-tier system as follows: indefinite for 
dysplasia (IND), low-grade dysplasia (LGD), 
and high-grade dysplasia (HGD) .3 4 IND is 
a category where the observed architectural 
and nuclear abnormalities are less diagnostic 
than those seen in clear-cut dysplasia, or 
when there are significant architectural/cyto-
logical atypical features but also significant 
concomitant inflammation such that reac-
tive atypia cannot be excluded. In clinical 
practice LGD and IND are often treated the 
same way in regard to surveillance.5 However, 
with the recent shift in the guidelines to abla-
tion of LGD due to a randomised control 
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trial showing benefit in regard to lack of progression to 
neoplasia, it is a bit unclear clinically how to manage IND 
patients.6 7 In addition, a recent multicentre study has 
shown that patients diagnosed with IND behave similarly 
to LGD in regard to biological behaviour.5 Triaging IND 
patients according to risk of future progression would 
help to limit unnecessary repeat endoscopies in patients 
at low risk and justify closer observation in patients at 
higher risk, perhaps even supporting early means of 
cancer prevention such as ablation.
Thus, other biomarkers may be helpful in risk stratifica-
tion in BE-IND. Currently, dysplasia is the only biomarker 
used to risk-stratify BE. Despite its widespread use, it is 
unclear whether surveillance endoscopy to detect this 
biomarker is useful.8–11 As a result research for other 
biomarkers, particularly molecular biomarkers, to help 
risk-stratify BE is under way.12–15 One potential biomarker 
that has been identified is mutational load (ML) as 
a measure of genetic aberration and instability.16 ML 
provides a measure of cumulative genomic instability at 
10 key genomic loci in patients with BE by assessing DNA 
damage in proximity to tumour suppressor genes asso-
ciated with progression to HGD and EA. BE tissue with 
a higher degree of genetic aberrations, specifically loss 
of heterozygosity (LOH) of tumour suppressor genes, 
progresses to more advanced disease.17
ML assessment can be determined using a commer-
cially available test (BarreGEN, Interpace Diagnostics, 
Pittsburgh, Pennsylvania, USA). The test quantifies the 
degree of cumulative genetic derangement of 10 genetic 
loci of tumour suppressor genes, specifically assessing 
the presence of LOH mutations and new alleles consis-
tent with microsatellite instability (MSI). The following 
genetic loci are tested, with their tumour suppressor 
genes in parentheses: 1p (CMM1, L-myc), 3p (VHL, 
HoGG1), 5q (MCC, APC), 9p (CDKN2A), 10q (PTEN, 
MXI1), 17p (TP53), 17q (RNF43, NME1), 18q (SMAD4, 
DCC), 21q (TFF1, PSEN2) and 22q (NF2).16 18 All LOH 
mutations are assigned a numerical value based on the 
degree of derangement. ML consists of a statistically 
derived weighted scoring system from 0 to 10, with 0 
representing the lowest level of genomic instability and 10 
representing the highest level of genomic instability.16 19
A recent case–control study evaluated the utility of ML 
in predicting progression to neoplasia (HGD or intramu-
cosal cancer) based on samples of only BE with LGD or 
non-dysplastic BE at baseline.16 Cases that progressed to 
neoplasia on follow-up (23 patients) were compared with 
controls (46 patients who did not progress to neoplasia). 
The mean ML was higher in cases that progressed than 
controls (2.21 vs 0.42, p<0.001). The study concluded 
that ML in preprogression tissue can predict progres-
sion to neoplasia in BE and thus may serve as a useful 
biomarker in surveillance of BE.
ML is proportional to the degree of dysplasia, and thus 
may serve as an adjunctive test in patients with equivocal 
histology. A retrospective study looked at 271 patients 
with varying degrees of dysplasia (IND, LGD and HGD).18 
The authors found that the ML correlated to the grade of 
dysplasia (1.1 vs 2.2 vs 3.3, respectively; correlation coef-
ficient=0.60, p<0.0001). The authors concluded that ML 
may be a useful adjunct to histological evaluation. Another 
retrospective study examined 877 microdissected targets 
from BE biopsies. Increasing ML correlated to increasing 
severe histology in regard to grade of dysplasia (correla-
tion coefficient=0.68, p<0.0001).19
The aim of this study is to determine if ML can help 
risk-stratify patients with BE-IND.
Methods
This is a retrospective review of patients diagnosed with 
BE-IND at North Shore University Hospital from 2013 to 
2017. A prospectively maintained database was searched 
for consecutive patients. The inclusion criteria included 
(1) diagnosis of BE-IND on an endoscopic exam without 
a concurrent diagnosis of true dysplasia elsewhere in 
the oesophagus; (2) underwent endoscopic surveillance 
for IND with Seattle protocol biopsies20; (3) underwent 
ML testing for risk stratification on the index endoscopy 
biopsies showing IND (preprogression tissue); and (4) 
had adequate follow-up of at least 1 year if no dysplasia 
was detected on subsequent exams. Exclusion criteria 
included the following: (1) underwent endoscopic abla-
tion; (2) lack of 1-year follow-up for patients who did not 
have dysplasia on a follow-up exam; (3) history of LGD or 
HGD; (4) dysplasia developing within 1 year of the initial 
endoscopy (as the dysplasia was likely present on the 
index exam); (5) presence of oesophagitis on histology 
or endoscopy; and (6) patient not on a medical antacid 
regimen.
ML testing was performed on baseline IND biopsy 
tissue blinded to the future progression status of patients 
(BarreGEN, Interpace Diagnostics). All cases in this series 
were re-examined by the pathologist and only targets that 
contained the IND were used. ML was measured using 
the formalin-fixed, paraffin-embedded (FFPE) tissue 
from biopsies taken at the time of baseline endoscopy. 
H&E-stained FFPE slides were microscopically examined 
by pathologists to identify representative areas of IND 
histology. H&E-stained slides were used to guide micro-
dissection of recut, unstained, 4 μm thick, FFPE slides. 
Slides were microdissected for the maximum number of 
histological targets with IND available for each patient. 
Microdissection was performed manually, targeting areas 
in which epithelial cells constituted 90% or more of the 
total cells removed. By microscopic estimation, no more 
than 10% of microdissected cells were stromal or inflam-
matory cells. Accuracy of all microdissections was care-
fully reviewed by two pathologists.
Selected areas for microdissection contained mainly 
epithelial cells. DNA from the microdissected targets 
was then prepared. PCR and quantitative capillary elec-
trophoresis of DNA were used to detect the presence of 
LOH and new alleles consistent with MSI of the selected 
DNA markers for the previously discussed 10 genetic loci 
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Table 1 Patient demographics
IND progressed to 
HGD
n=2
IND progressed to 
LGD
n=6
No IND 
progression
n=20
All IND
n=28
Age (years), mean 57 61.17 65.2 63.75
Sex (male) 2/2 (100%) 5/6 (83.33%) 10/20 (50%) 17/28 (60.71 %)
Hiatal hernia 1/2 (50%) 1/6 (16.67%) 7/20 (35%) 9/28 (32.14%)
Length mean (cm) 7.5 4 3.68 4.04
Patients had 1-year follow-up exam 2/2 (100%) 6/6 (100%) 20/20 (100%) 28/28 (100%)
2-year follow-up 2/2 (100%) 4/6 (66.67%) 16/20 (80%) 22/28 (78.57%)
3-year follow-up 2/2 (100%) 2/6 (33.33%) 11/20 (55%) 15/28 (53.57%)
HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia.
of tumour suppressor genes. For each microdissected 
tissue, it was determined whether each LOH mutation is 
of low (50%–75% of the DNA contained LOH) or high 
(>75% of the DNA contains LOH mutations) clonality. 
The sum of the clonality of each genetic loci is the ML.19
Two gastrointestinal pathologists (GL and RMT), with 
extensive experience in a high-volume Barrett’s tertiary 
care referral centre, reviewed all initial IND histology 
and follow-up histology. For the purposes of this study, 
the histology was rereviewed to ensure IND was an accu-
rate diagnosis prior to preparation for ML analysis. This 
rereview also served to help locate the area on the tissue 
where ML would be measured. It should be noted that 
in our institution, the current clinical practice is that 
any diagnosis of dysplasia including IND is reviewed at 
the gastrointestinal pathology consensus meeting, where 
three to five gastrointestinal pathologists are present.
Patient characteristics were abstracted from the 
medical chart. Data analysis was separated into two 
groups. The first group was subjects with BE and IND 
on the index endoscopy who developed dysplasia (LGD, 
HGD or intramucosal cancer) on subsequent follow-up 
at least 1 year after the index pathology of IND. The 
second group was subjects with BE and IND on the index 
endoscopy who did not develop dysplasia on subsequent 
follow-up at least 1 year after the index pathology of IND. 
These patients had non-dysplastic histology or continued 
IND histology on follow-up exams. The two groups were 
compared to determine if there is an ML cut-off that can 
predict progression to dysplasia or neoplasia (HGD/
intramucosal cancer) in the IND cohort within 1 year of 
the index endoscopy.
χ2 and Fisher’s exact tests were used to compare cate-
gorical variables, and the Student’s t-test was used for 
continuous variables. All analyses were conducted using 
SAS V.9.4.
results
Thirty-five patients who met the inclusion criteria were 
identified, and seven who met the exclusion criteria were 
excluded (three with oesophagitis, three without 1-year 
follow-up and one not on antacid medication). The study 
analysed 28 consecutive IND patients at baseline biopsy, 
61% were male with a mean age of 64 years (table 1). 
All IND pathology was confirmed by the pathologists in 
this study without disagreement. All patients had 1-year 
follow-up endoscopy, with corresponding follow-up 
biopsy indicating no progression or indicating progres-
sion to LGD or HGD, with 22 patients (79%) having 2 
years and 15 patients (54%) having 3 years of endoscopic 
surveillance follow-up. Of all IND patients, six eventually 
progressed to LGD (21%) and two to HGD (7%). The 
baseline mean BE segment length was similar in IND 
patients who later progressed to LGD (4.0 cm) versus 
those who did not (3.7 cm), but significantly longer in 
patients who progressed to HGD (7.5 cm). Of all patients 
with baseline IND, 29% (8/28) progressed to LGD or 
HGD, while only 7% (2/28) progressed to HGD.
For analysis, ML scores in IND biopsies were grouped 
into numerical categories shown in tables 2 and 3. 
Many IND patients who did not progress to LGD or 
HGD lacked all detectable genomic instability (10/20) 
(ML=0; table 2). By contrast 88% (7/8) of patients who 
progressed to LGD or HGD had at least some level of 
genomic instability detected in their IND biopsy (ML 
≥0.5). The sensitivity and specificity for identifying 
patients who would later progress to LGD or HGD at this 
ML threshold were 88% and 50%, respectively (table 2). 
Using this ML threshold for genomic instability (ML 
≥0.5) separated patients who had an initial 29% risk of 
progression to LGD or HGD at baseline into two, more 
refined risk categories: (1) those at lower risk of progres-
sion to LGD or HGD (9% risk of progression) and (2) 
those at higher risk of progression to LGD or HGD (41% 
risk of progression) (9% vs 41%, p=0.07). Higher levels 
of genomic instability provided higher specificity for 
predicting which IND patients would progress but at the 
expense of lower sensitivity for progression.
In contrast, patients who progressed to HGD had 
comparably higher levels of genomic instability at 
baseline IND biopsy (ML ≥1.5; table 3). The sensitivity 
and specificity for identifying patients who would later 
progress to HGD at this ML threshold were 100% and 
85%, respectively. Using this ML threshold for genomic 
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Table 2 ML performance in predicting future progression to LGD or HGD in IND patients at baseline
No IND progression 
LGD or HGD
IND progressed to 
LGD or HGD
Specificity 
(%)
Sensitivity 
(%)
% IND that progressed to LGD 
or HGD
ML=0 10 1 NA NA 9% of IND progressed
(lower risk)
ML=0.5–0.75 3 3 50 88 41% of IND progressed
(higher risk)ML=1.0–1.25 4 1 65 50
ML=1.5–1.75 2 1 85 38
ML ≥2 1 2 95 25
Total 20 8 Overall 29% of IND progressed
HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia; ML, mutational load; NA, not available.
Table 3 ML performance in predicting future progression to HGD in IND patients at baseline
No IND progression 
to HGD
IND progressed 
to HGD Specificity (%) Sensitivity (%)
% IND that progressed to 
HGD
ML=0 11 0 NA NA 0% progressed
(low risk)ML=0.5–0.75 6 0 42 100
ML=1.0–1.25 5 0 65 100
ML=1.5–1.75 2 1 85 100 33% progressed (higher risk)
ML ≥2 2 1 92 50
Total 26 2 Overall 7% of IND progressed
HGD, high-grade dysplasia; IND, indefinite for dysplasia; ML, mutational load; NA, not available.
instability (ML ≥1.5) separated patients who had an 
initial 7% risk of progression to HGD at baseline into 
two, more refined risk categories: (1) those at lower risk 
of progression to HGD (0% rate of progression) and (2) 
those at higher risk of progression to HGD (33% rate of 
progression) (0% vs 33%, p=0.005). Again, higher levels 
of genomic instability provided higher specificity for 
predicting which IND patients would progress to HGD.
dIscussIon
In this study we show that ML can help risk-stratify 
patients who may progress to dysplasia in patients with BE 
with IND. In this study 29% progressed to dysplasia (LGD 
and HGD) and 7% progressed to HGD. This is in line 
with other single-centre series from tertiary care centre. 
Previous studies have shown an annual progression rate 
of 12.9%–25% depending on the series.21–23 Seven out 
of the eight patients who progressed to dysplasia in our 
study had some level of genomic instability. ML had 
been shown previously to help risk-stratify patients with 
non-dysplastic BE or with LGD in regard to progression 
to HGD.16 As discussed earlier, these IND patients can 
be difficult to manage and require more intense surveil-
lance. Thus further risk stratification can be helpful in 
this subgroup of patients.
This study is novel in that it is the first to examine if 
ML can be a predictor of progression to true dysplasia in 
patients with BE and IND. Previous studies have shown 
ML to be a predictor for progression in non-dysplastic 
disease.18 19 Other studies have looked at DNA content 
abnormalities from FFPE tissue, such as aneuploidy 
measured by flow cytometry, in predicting progression 
from IND to dysplasia.23 24 These studies show that DNA 
flow cytometry can risk-stratify patients with BE-IND who 
will progress to dysplasia.
Our results show that patients with an ML above 0.5 
should be considered for more frequent surveillance 
compared with those with no ML, as these patients had 
a higher risk of progression to low-grade and high-grade 
dysplasia (41% vs 9%, p<0.07). The result was not signif-
icant likely due to the small sample size. On the other 
hand, an ML above 1.5 statistically predicted progres-
sion to HGD versus those with an ML below 1.5 (33% 
vs 0%, p=0.005). Based on this, an ML above 1.5 should 
be strongly considered for frequent surveillance and 
perhaps even advanced imaging if no obvious lesions are 
visualised given the focal nature of dysplasia.
Not surprisingly, our results are more robust for risk 
stratification in regard to patients who eventually develop 
HGD compared with those patients who progressed to 
LGD. This could be related to the inherent issues with 
the classification of LGD,25–27 which include high interob-
server variability among expert pathologists. A sensitivity 
and specificity of 100% and 85% for an ML above 1.5 for 
progression to HGD in this cohort support its use as a risk 
stratification tool in BE for progression to HGD.
The strengths of our study include a true IND cohort. 
Patients’ histology from preprogression tissue was rere-
viewed by experts in gastrointestinal pathology. In addi-
tion patients were excluded if there were any signs of 
5Trindade AJ, et al. BMJ Open Gastro 2019;6:e000268. doi:10.1136/bmjgast-2018-000268
Open access
oesophagitis on pathology or if patients were not opti-
mised on a medical antacid regimen.
Our study does have limitations. This is a single-
centre, retrospective study. We decided to make this 
a single-centre study to control for heterogeneity in 
pathological classifications. It also afforded us the oppor-
tunity to allow our pathologists to review all baseline 
pathology. In addition the sample size is relatively small 
at 28 patients. Another limitation is that despite patients 
undergoing standard-of-care Seattle protocol biopsies, 
it is possible that LGD or HGD is missed on the initial 
exam if a dysplastic area was not seen on endoscopy and 
missed on random biopsies, especially since this cohort 
consists of patients with long-segment Barrett’s. This is a 
known phenomenon that can occur in any surveillance 
programme.11 28 Finally the follow-up period that was 
required for this study was only 1 year (54% of patients 
had 3-year follow-up). It is possible that patients who had 
ML levels above 0.5 and did not progress may progress to 
low-grade or high-grade dysplasia on further follow-up.
Despite the limitations our pilot study shows that ML 
may be a useful test for risk stratification in BE-IND. It 
should be noted that we are not advocating ablation 
based on ML levels. The decision for ablation should be 
dictated by the presence of dysplasia, as per the guide-
lines. However we do feel that ML can dictate surveil-
lance intervals and thus help risk-stratify patients. Larger 
studies in the future on a BE-IND cohort may give more 
insight into the sensitivity and specificity of the test. In 
our study we had one patient with a high ML (>2) with 
over 3 years of follow-up who never developed dysplasia. 
On the other hand, we had a patient who developed LGD 
who never had a measurable ML. Given the small cohort, 
this affects the sensitivity and specificity of the test, per 
table 2. Larger studies would be able to account for these 
extremes and give a better estimate of the sensitivity and 
specificity of ML in predicting progression to dysplasia. 
Despite the small numbers it seems that the sensitivity 
and specificity for development of HGD at ML of 1.5–1.75 
(100, 85%) hold promise to be a possible indicator of 
BE-IND to develop to HGD. Larger prospective observa-
tional studies are needed to confirm our findings given 
only two patients in the cohort progressed to HGD.
In summary, IND patients had a low risk of progres-
sion to HGD but a significantly higher risk of progres-
sion to any to type of dysplasia (LGD or HGD). Genomic 
instability can further refine risk in these patients by 
dividing them into categories: (1) those at lower risk of 
progression to dysplasia and (2) those at higher risk of 
progression to dysplasia compared with the risk initially 
conferred by their baseline pathology diagnosis of IND 
alone. Our results are consistent with those of previous 
studies demonstrating that ML can be a useful biomarker 
in identifying patients with BE at risk of future progres-
sion to EA, allowing for closer surveillance or cancer 
preventative treatment in patients at higher risk of 
progression and avoiding unnecessary interventions in 
those at lower risk.
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